Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt Likely To Shed SSL Brands As Profits Trickle In

This article was originally published in The Tan Sheet

Executive Summary

Reckitt Benckiser's acquisition of SSL has yet to produce sizeable returns for the company, leading the firm to consider spinning off some acquired brands, company officials said.

You may also be interested in...

Reckitt Continues Asian Push With $724M Paras Purchase

Reckitt Benckiser continues expanding its Asian business with the purchase of Paras Pharmaceuticals Ltd., a top OTC manufacturer in India, where nonprescription drug sales are growing 23% annually.

Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU

Emerging markets, the key driver for Reckitt Benckiser's nearly 20% net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S.

Reckitt Would Add Durex, Scholl Brands With SSL Acquisition

Reckitt Benckiser moves again to grow its consumer products business, particularly in Asian markets, with an offer to acquire Durex condoms and Scholl foot care products manufacturer SSL International

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts